Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia

NCT03669549 is registered in ClinicalTrials.gov with Millendo Therapeutics US, Inc. as lead sponsor.

NCT NCT03669549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03669549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia
Lead sponsor
Millendo Therapeutics US, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
July 11, 2018
Completion date
July 12, 2020
Enrollment
15 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

congenital adrenal hyperplasia